Market growth is being driven by advanced therapies involving Pfizer, Novartis, and Merck.
1 report, 1 independent
Updated Aug 13
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Market growth is being driven by advanced therapies involving Pfizer, Novartis, and Merck.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Jefferies maintained a Buy rating on Merck & Co., citing revenue growth from Keytruda and vaccine sales stability.Sub-event
- Merck's stock change was less than S&P 500's daily loss and outperformed the Medical sector loss on July 19, 2025.Sub-event
Market upward trend influenced Merck's share increase, aided by Health Canada approval and Fed rate cuts.1 source
Keep exploring
The entities involved
-
Merck
public company in Indonesia
Related events
- Merck's stock price increased following positive drug performance involving Summit Therapeutics.
- Healthcare stocks surged to record highs on August 19, 2026, amid market excitement over drug breakthroughs involving Moderna, Amgen, and Merck.
- Merck's Animal Health segment is performing well, and the company discussed transformation during a meeting with Morgan Stanley.
- Bank of America shared insights from Merck's CMO regarding the ongoing financing deal.
- Bank of America led Merck's $5 billion financing deal, alongside bond sales by automakers, amid market anticipation of FED rate decisions.
Coverage
Newest first; wire copies grouped- Simply Wall St.Merck (MRK) Announces Positive Phase 3 Trial Results For KEYTRUDA In Bladder Cancer Treatment Merck recently announced positive topline results from its Phase 3 KEYNOTE-905 trial, showcasing efficacy